Zhejiang Xianju Pharmaceutical (002332) Fundamentals 2026 — P/E 20.5x, Revenue Analysis | SniperIQ
Zhejiang Xianju Pharmaceutical (002332) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥8.3B, trading at ¥8.35 on the SHZ. This SniperIQ fundamentals page covers Zhejiang Xianju Pharmaceutical's valuation (P/E 20.5x, P/B 1.4x), profitability (net margin 10.9%), revenue (¥3.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zhejiang Xianju Pharmaceutical's market cap?
Zhejiang Xianju Pharmaceutical (002332) has a market capitalization of approximately ¥8.3B, trading at ¥8.35 on the SHZ. Market cap moves with the live share price.
What is Zhejiang Xianju Pharmaceutical's P/E ratio?
Zhejiang Xianju Pharmaceutical's trailing twelve-month P/E ratio is 20.5x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zhejiang Xianju Pharmaceutical?
Zhejiang Xianju Pharmaceutical runs a net profit margin of 10.9%, a gross margin of 61.7%, and an operating margin of 11.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zhejiang Xianju Pharmaceutical generate?
Zhejiang Xianju Pharmaceutical reported revenue of ¥3.8B for fiscal year 2025, with net income of ¥450M and earnings per share (EPS) of 0.45. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zhejiang Xianju Pharmaceutical pay a dividend?
Zhejiang Xianju Pharmaceutical offers a trailing dividend yield of about 3.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zhejiang Xianju Pharmaceutical financially healthy?
Zhejiang Xianju Pharmaceutical carries a debt-to-equity ratio of 0.03x and a current ratio of 3.32x, with a market beta of 0.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zhejiang Xianju Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhejiang Xianju Pharmaceutical (002332) the key facts are: market cap ¥8.3B, P/E 20.5x, revenue ¥3.8B, 52-week range 7.92-11.79. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zhejiang Xianju Pharmaceutical's full fundamentals live
Get Zhejiang Xianju Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.